AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9646889 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 242
Study 7994224 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment consisting of cleaning, depuration and motivation
Number of subjects: 82
Study 2455442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 20 mg of PEP/20 ml of saline for 4 weeks
Number of subjects: 116
Study 2455442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 40 mg of PEP/20 ml of saline for 4 weeks
Number of subjects: 116
Study 2455442 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly instillation of 20 mg of PEP/20 ml of saline for 8 weeks after TUR
Number of subjects: 116
Study 2455442 — intervention group
Group type: COMPARATOR
Intervention: TUR alone
Number of subjects: 116
Study 30646884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Training (CRT)
Number of subjects: 65
Study 30646884 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 65
Study 28402515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 52
Study 28402515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 52
Study 26163480 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic glasses during bimanual task intervention
Number of subjects: 21
Study 26163480 — intervention group
Group type: COMPARATOR
Intervention: Neutral glasses during bimanual task intervention
Number of subjects: 21
Study 22240754 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese men
Number of subjects: 903
Study 22240754 — intervention group
Group type: COMPARATOR
Intervention: White men
Number of subjects: 903
Study 22240754 — intervention group
Group type: COMPARATOR
Intervention: Japanese-American men
Number of subjects: 903
Study 21980001 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG/OHT black subjects
Number of subjects: 91
Study 21980001 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG/OHT white subjects
Number of subjects: 91
Study 21980001 — intervention group
Group type: COMPARATOR
Intervention: Healthy black controls
Number of subjects: 91
Study 21980001 — intervention group
Group type: COMPARATOR
Intervention: Healthy white controls
Number of subjects: 91
Study 21980001 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 91
Study 21980001 — intervention group
Group type: EXPERIMENTAL
Intervention: White participants
Number of subjects: 91
Study 18289228 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt-based high molecular weight HES solution (670/0.75)
Number of subjects: 74
Study 18289228 — intervention group
Group type: COMPARATOR
Intervention: Saline-based low molecular weight HES solution (130/0.4)
Number of subjects: 74
Study 16691051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored falls prevention exercise (16 weeks, 3 times a week, 50 min each session)
Number of subjects: 59
Study 14763031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg every 12 hours) for a mean period of 14.5 months (range: 6-30 months)
Number of subjects: 37
Study 14763031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study 11076423 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnerot (magnesium orotate) 500 mg tablets, daily dose 3000 mg for 6 months
Number of subjects: 84
Study 11076423 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 8955868 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole-D (10 mg astemizole/240 mg pseudoephedrine)
Number of subjects: 12
Study 8955868 — intervention group
Group type: COMPARATOR
Intervention: Loratadine-D (5 mg loratadine/120 mg pseudoephedrine)
Number of subjects: 12
Study 1550052 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg manganese daily
Number of subjects: 47
Study 1550052 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron daily
Number of subjects: 47
Study 1550052 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mineral supplements daily
Number of subjects: 47
Study 1550052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3912955 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping technique treatment (10 one-hour sessions)
Number of subjects: 24
Study 3912955 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (no treatment initially, followed by similar treatment)
Number of subjects: 24
Study 30048609 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (amoxicillin, clarithromycin, and omeprazole) for 10 days
Number of subjects: 149
Study 26481226 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal multiparametric 3‐tesla MRI followed by cognitive systematic prostatic biopsy (CSPB)
Number of subjects: 200
Study 26481226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MRI)
Number of subjects: 200
Study 24574085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation
Number of subjects: 32
Study 24574085 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 22584544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl wafer (100 μg)
Number of subjects: 24
Study 22584544 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl (100 μg)
Number of subjects: 24
Study 20425759 — intervention group
Group type: EXPERIMENTAL
Intervention: FV capsules
Number of subjects: 117
Study 20425759 — intervention group
Group type: EXPERIMENTAL
Intervention: FVB capsules
Number of subjects: 117
Study 20425759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 17672262 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide liner (Hydro C)
Number of subjects: 39
Study 17672262 — intervention group
Group type: COMPARATOR
Intervention: Gutta-percha sheet
Number of subjects: 39
Study 17672262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 39
Study 15689195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (10 mg)
Number of subjects: 113
Study 15689195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (2 g)
Number of subjects: 113
Study 15689195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 113
Study 11981123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 365) informed of test results and invited for further assessment by a senior physician.
Number of subjects: 978
Study 11981123 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 302) left with information of high GT value and followed up with laboratory checkups every 2nd year.
Number of subjects: 978
Study 9730078 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 336
Study 7614898 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (100 mg five times daily until onset of labour, followed by intravenous zidovudine 2 mg/kg over 1 hour then 1 mg/kg.h until delivery)
Number of subjects: 400
Study 7614898 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine syrup (2 mg/kg administered 6-hourly for 6 weeks)
Number of subjects: 400
Study 7614898 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 400
Study 1975321 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK, 1.5 MU infused intravenously over 30‐60 min)
Number of subjects: 12490
Study 1975321 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (tPA, 100 mg infused intravenously over 3 h)
Number of subjects: 12490
Study 1975321 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (12,500 U subcutaneously twice daily until discharge, starting 12 h after beginning the tPA or SK infusion)
Number of subjects: 12490
Study 1975321 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 12490
Study 1975321 — intervention group
Group type: EXPERIMENTAL
Intervention: SK and heparin
Number of subjects: 12490
Study 1975321 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA and heparin
Number of subjects: 12490
Study 1975321 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 12490
Study 1975321 — intervention group
Group type: EXPERIMENTAL
Intervention: SK and tPA
Number of subjects: 12490
Study 4913961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ergotamine tartrate (2 or 3 mg)
Number of subjects: 79
Study 4913961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 4913961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ergotamine tartrate
Number of subjects: 79
Study 30997721 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated prevention program
Number of subjects: 388
Study 30997721 — intervention group
Group type: COMPARATOR
Intervention: Study skills control
Number of subjects: 388
Study 30997721 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 388
Study 28668386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation group (R-CHOP-14 followed by R-MAD plus BEAM and autologous stem-cell transplantation)
Number of subjects: 399
Study 28668386 — intervention group
Group type: COMPARATOR
Intervention: No transplantation group (full course of rituximab-dose-dense chemotherapy)
Number of subjects: 399
Study 28668386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation group
Number of subjects: 399
Study 28668386 — intervention group
Group type: COMPARATOR
Intervention: No transplantation group
Number of subjects: 399
Study 28668386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 399
Study 26036621 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving stress and life stress
Number of subjects: 300
Study 24007322 — intervention group
Group type: EXPERIMENTAL
Intervention: 63 Gy in 20 fractions (4 fractions/week) (Arm 2)
Number of subjects: 124
Study 24007322 — intervention group
Group type: COMPARATOR
Intervention: 76 Gy in 38 fractions (5 fractions/week) (Arm 1)
Number of subjects: 124
Study 21719078 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-13 (6 mg/kg intravenously)
Number of subjects: 36
Study 21719078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal corticosteroid (fluticasone)
Number of subjects: 36
Study 21719078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19327467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesylate (20 mg) with 5% dextrose solution
Number of subjects: 704
Study 19327467 — intervention group
Group type: COMPARATOR
Intervention: Control (without nafamostat mesylate)
Number of subjects: 704
Study 16352815 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (92 mg/kg/d)
Number of subjects: 61
Study 16352815 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (43 mg/kg for 5.7 d/wk)
Number of subjects: 61
Study 16352815 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 61
Study 16352815 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 61
Study 15285851 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole (30 mg per day for 4 days)
Number of subjects: 19
Study 15285851 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole (10 mg per day for 4 days)
Number of subjects: 19
Study 15285851 — intervention group
Group type: COMPARATOR
Intervention: control (without lansoprazole or rabeprazole)
Number of subjects: 19
Study 10708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypercapnia (Paco2 from 40+/‐3 to 52+/‐3 torr)
Number of subjects: 10
Study 10708167 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypocapnia (Paco2 from 41+/‐3 to 34+/‐3 torr)
Number of subjects: 10
Study 9094882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube feeding
Number of subjects: 17
Study 9094882 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 17
Study 8195854 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 50
Study 8195854 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 50
Study 3721943 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) 1g, 2g, 3g
Number of subjects: 10
Study 3721943 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 3 mg
Number of subjects: 10
Study 31630052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 0
Study 31630052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30242986 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-therapy
Number of subjects: 240
Study 30242986 — intervention group
Group type: COMPARATOR
Intervention: Mono-therapy
Number of subjects: 240
Study 26781004 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r
Number of subjects: 75
Study 26781004 — intervention group
Group type: COMPARATOR
Intervention: LPV/r
Number of subjects: 75
Study 23244034 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect intervention
Number of subjects: 5
Study 23244034 — intervention group
Group type: COMPARATOR
Intervention: Greedy divisions of money or labor
Number of subjects: 5
Study 23244034 — intervention group
Group type: COMPARATOR
Intervention: Equal divisions of money or labor
Number of subjects: 5
Study 23244034 — intervention group
Group type: COMPARATOR
Intervention: Generous divisions of money or labor
Number of subjects: 5
Study 23262045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prograf
Number of subjects: 82
Study 23262045 — intervention group
Group type: COMPARATOR
Intervention: Advagraf
Number of subjects: 82
Study 20605872 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein omnivorous diet (30% energy from protein with 40% from lean pork)
Number of subjects: 82
Study 20605872 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein vegetarian diet (18% energy from protein via lacto-ovo vegetarian sources)
Number of subjects: 82
Study 20605872 — intervention group
Group type: COMPARATOR
Intervention: Nonmeat protein sources (16% energy from protein)
Number of subjects: 82
Study 20605872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken (26% energy from protein)
Number of subjects: 82
Study 20605872 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef (26% energy from protein)
Number of subjects: 82
Study 20605872 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 82
Study 18398024 — intervention group
Group type: EXPERIMENTAL
Intervention: Having health insurance coverage
Number of subjects: 2887
Study 18398024 — intervention group
Group type: EXPERIMENTAL
Intervention: Having health insurance coverage (men)
Number of subjects: 2887
Study 18398024 — intervention group
Group type: EXPERIMENTAL
Intervention: Having health insurance coverage (women)
Number of subjects: 2887
Study 18398024 — intervention group
Group type: EXPERIMENTAL
Intervention: Having health insurance coverage (adjusted for age and income, men)
Number of subjects: 2887
Study 18398024 — intervention group
Group type: EXPERIMENTAL
Intervention: Having health insurance coverage (adjusted for age and income, women)
Number of subjects: 2887
Study 15812731 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet/video-delivered intervention (8 sessions)
Number of subjects: 104
Study 11919104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised levo-adrenaline (3 mg in 3 ml)
Number of subjects: 38
Study 11919104 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline placebo
Number of subjects: 38
Study 10394803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild controlled hypothermia (Core temperature = 33‐35 degrees C)
Number of subjects: 5
Study 10394803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 5
Study 7595101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol ester margarine (3 g/day)
Number of subjects: 15
Study 1850942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 8
Study 1850942 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 8
Study 7053889 — intervention group
Group type: EXPERIMENTAL
Intervention: RAO projection
Number of subjects: 32
Study 7053889 — intervention group
Group type: COMPARATOR
Intervention: LAO projection
Number of subjects: 32
Study 7053889 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus FWHM
Number of subjects: 32
Study 7053889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential studies
Number of subjects: 32
Study 7053889 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall motion assessment
Number of subjects: 32
Study 30516029 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-gene immune-related risk signature
Number of subjects: 285
Study 30516029 — intervention group
Group type: EXPERIMENTAL
Intervention: High-immune risk patients
Number of subjects: 285
Study 30516029 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene set enrichment analysis (GSEA) results
Number of subjects: 285
Study 28225739 — intervention group
Group type: EXPERIMENTAL
Intervention: Damage Control Laparotomy (DCL)
Number of subjects: 329
Study 28225739 — intervention group
Group type: COMPARATOR
Intervention: Definitive Surgical Management
Number of subjects: 329
Study 25517348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial treatment plus usual care
Number of subjects: 500
Study 25517348 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 500
Study 23975185 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training three times a week for 6 weeks during pulmonary rehabilitation
Number of subjects: 39
Study 23975185 — intervention group
Group type: COMPARATOR
Intervention: Control group received only the 6-week pulmonary rehabilitation program
Number of subjects: 39
Study 22108352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) correction
Number of subjects: 114
Study 22108352 — intervention group
Group type: COMPARATOR
Intervention: Contact lens correction
Number of subjects: 114
Study 19740082 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 60
Study 19740082 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 60
Study 17006667 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 30
Study 15567189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine treatment for 8 weeks
Number of subjects: 25
Study 15567189 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 25
Study 11395198 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmolality of 300, 600, 850, and 1100 mOsm during intramuscular injection of 0.5 ml vaccine suspensions
Number of subjects: 20
Study 11395198 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 20
Study 9121645 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of meglumine ioglycate, 300 mg/ml
Number of subjects: 60
Study 9121645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg of meglumine ioglycate, 300 mg/ml
Number of subjects: 60
Study 9121645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 ml/kg of meglumine ioglycate, 300 mg/ml
Number of subjects: 60
Study 8398292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) - 9 instillations
Number of subjects: 437
Study 8398292 — intervention group
Group type: COMPARATOR
Intervention: BCG-Tice - 6 weekly instillations
Number of subjects: 437
Study 8398292 — intervention group
Group type: COMPARATOR
Intervention: BCG-RIVM - 6 weekly instillations
Number of subjects: 437
Study 8398292 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (MMC, BCG-Tice, BCG-RIVM)
Number of subjects: 437
Study 3297218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose prednisone (0.5 mg/kg body weight)
Number of subjects: 143
Study 3297218 — intervention group
Group type: COMPARATOR
Intervention: High dose prednisone (2.0 mg/kg body weight)
Number of subjects: 143
Study 31327047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet plus Bacillus coagulans supplementation (109 B. coagulans spores and 400 mg inulin)
Number of subjects: 50
Study 31327047 — intervention group
Group type: COMPARATOR
Intervention: Low FODMAP diet alone (placebo with 500 mg rice starch)
Number of subjects: 50
Study 29404948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery learning course with visual and dermoscopic assessment, diagnosis and management, and deliberate practice with feedback.
Number of subjects: 89
Study 29404948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery learning course
Number of subjects: 89
Study 25257848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise (FIO2 = 0·12‐0·13)
Number of subjects: 7
Study 25257848 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise (FIO2 = 0·21)
Number of subjects: 7
Study 24920046 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Based Telemedicine
Number of subjects: 168
Study 24920046 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 168
Study 22843218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection (painful)
Number of subjects: 15
Study 22843218 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection (control)
Number of subjects: 15
Study 20716636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood individuals
Number of subjects: 0
Study 20716636 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood individuals
Number of subjects: 0
Study 20716636 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood individuals
Number of subjects: 0
Study 20716636 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood individuals
Number of subjects: 0
Study 18561925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation (NAPS)
Number of subjects: 80
Study 18561925 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and meperidine (M/M)
Number of subjects: 80
Study 16105183 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (multiple intravenous doses)
Number of subjects: 130
Study 16105183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130